How many insider trades does FilingIQ track for CAI?

FilingIQ tracks 211 Form 4 insider transactions for CAI (Caris Life Sciences, Inc.), covering filings from Oct 24, 2017 onwards. 12 of those were filed in the last 90 days.

Are CAI insiders net buyers or net sellers?

Across the full Form 4 history for CAI, 11 transactions (5%) were open-market purchases and 27 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CAI insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CAI in?

Caris Life Sciences, Inc. (CAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.51B.

CAI insider trading

NasdaqGS Healthcare

Caris Life Sciences, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

211

Last 90 days

Buys / sells

5% / 13%

Market cap

$4.51B

About Caris Life Sciences, Inc.

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exome sequencing (WES)/ whole transcriptome sequencing (WTS) tissue-based molecular profiling solutions; Caris Assure Platform WES/WTS blood-based molecular profiling solutions; Precision Whole Genome Platform, a whole genome sequencing (WGS) blood- and tissue-based profiling solutions; and Caris Detect, a WGS-based multi-cancer early detection solution; Caris WGS MRD a WGS and digital droplet polymerase reaction-based minimal residual disease solution; and Caris ChromoSeq, a WGS and WTS based assay for therapy selection in hematological cancers. It also offers pharma research and development services comprising laboratory delivery, strategic data, and research services to biopharmaceutical customers. The company provides its precision oncology solutions to customers, such as hospitals, institutions and patients. The company was founded in 2008 and is headquartered in Irving, Texas.

Company website: www.carislifesciences.com

CAI insider activity at a glance

FilingIQ has scored 211 insider transactions for CAI since Oct 24, 2017. The most recent filing in our index is dated May 11, 2026.

Across the full history, 11 open-market purchases and 27 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CAI insider trades is 61.4/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CAI trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CAI?: FilingIQ tracks 211 Form 4 insider transactions for CAI (Caris Life Sciences, Inc.), covering filings from Oct 24, 2017 onwards. 12 of those were filed in the last 90 days.
Are CAI insiders net buyers or net sellers?: Across the full Form 4 history for CAI, 11 transactions (5%) were open-market purchases and 27 (13%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CAI insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CAI in?: Caris Life Sciences, Inc. (CAI) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.51B.

Methodology & sources

Every CAI insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.